Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2012, vol. 21, nr 5, September-October, p. 559–561

Publication type: editorial article

Language: English

Hyponatremia Now – A Goldmine or a Dead End?

Hiponatremia dziś – żyła złota czy ślepa uliczka?

Peter Gross1,

1 Medical Clinic III, C.G. Carus University Hospital, Dresden, Germany


Hyponatremia is a clinically relevant disorder. Ten to twenty per cent of patients in hospitals are affected by it. Hyponatremia is found to occur in almost every clinical department. Recently, vasopressin antagonists have been licensed to treat hyponatremia of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). They provide physicians with the first specific and effective therapy of this hyponatremia. This opens up new avenues for clinical research into the symptoms, findings and consequences of hyponatremia.


Hiponatremia jest zaburzeniem istotnym klinicznie. Cierpi na nie 10–20% pacjentów szpitali. Hiponatremia występuje niemal na każdym oddziale klinicznym. Ostatnio zaakceptowano antagonistów wazopresyny do leczenia hiponatremii w zespole nieprawidłowego wydzielania hormonu antydiuretycznego (SIADH). Te leki dają lekarzom dostęp do skutecznej terapii tego rodzaju hiponatremii. Otwiera to nowe możliwości badań klinicznych objawów, wyników i skutków hiponatremii.

Key words

hyponatremia, vasopressin antagonist

Słowa kluczowe

hiponatremia, antagoniści wazopresyny

References (34)

  1. Anderson RJ, Chung HM, Kluge R, Schrier RW: Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985, 102, 164–168.
  2. Miller M, Morley JE, Rubenstein LZ: Hyponatremia in a nursing home population. J Am Geriatr Soc 1995, 43, 1410–1413.
  3. Upadhyay A, Jaber BL, Madias NE: Incidence and prevalence of hyponatremia. Am J Med 2006, 119(7 Suppl 1), 30–35.
  4. Hantman D, Rossier B, Zohlman R, Schrier R: Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone: an alternative treatment to hypertonic saline. Ann Intern Med 1973, 78, 870–875.
  5. Forrest JN, Cox M, Hong C, Morrison G, Bia M, Singer I: Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978, 298, 173–177.
  6. Miller PD, Linas SL, Schrier RW: Plasma demeclocycline levels and nephrotoxicity. JAMA 1980, 243, 2513– 2515.
  7. Decaux G, Waterlot Y, Genette F, Mockel J: Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med 1981, 304, 329–330.
  8. Sarnaik AP, Meert K, Hackbarth R, Fleischmann L: Management of hyponatremic seizures in children with hypertonic saline: a safe and effective strategy. Crit Care Med 1991, 19(6), 758–762.
  9. Gheorghiade M, Gottlieb SS, Udelson J.E, Konstam MA, Czerwiec F, Ouyang J: Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006, 97, 1064–1067.
  10. Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH: Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007, 2, 1110–1117.
  11. Soupart A, Decaux G: Efficacy and tolerance of vaptans compared to urea for longterm treatment of patients with SIADH. A prospective study. Acta Clin Belgica 2009, 563. 64–66.
  12. Adrogué HJ: Consequences of inadequate management of hyponatremia. Am J Nephrol 2005, 25, 240–249.
  13. Hoorn E.J, Lindemans J, Zietse R: Development of severe hyponatremia in hospitalized patients: treatmentrelated risk factors and inadequate management. Nephrol Dial Transplant 2006, 21, 70–76.
  14. Huda MSB, Boyd A, Skagen K, Wile D, van Heyningen C, Watson I et al.: Investigation and management of severe hyponatremia in a hospital setting. Postgrad Med J 2006, 82, 216–219.
  15. Thibonnier M, Coles P, Thibonnier A, Shoham M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001, 41, 175–202.
  16. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW: Aquaretic effects of lixivaptan, an oral, nonpeptide, selective V2 receptor vasopressin antagonist, in New York association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006, 47, 1615–1621.
  17. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355, 2099–2112.
  18. Velez JCQ, Dopson SJ, Sanders DS, Delay TA, Arthur JM: Intravenous conivaptan for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a singlecentre experience. Nephrol Dial Transplant 2010, 25, 1524–1531.
  19. Berl T, Quittnat-Pelletier F, Verbalis G, Schrier RW, Bichet DG, Ouyang J et al.: Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010, 21, 705–712.
  20. Gines P, Wong F, Watson H, Milutinovic S, Arbol LR, Olteanu D: Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008, 48, 204–213.
  21. Schrier RW, Berl T: Nonosmolar factors affecting renal water excretion. N Engl J Med 1975, 292, 141–145.
  22. Gross P, Ketteler M, Hausmann C, Reinhard C, Schömig A, Hackenthal E: Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients. Klin Wochenschr 1988, 66, 662–669.
  23. Ellison DH, Berl T: The syndrome of inappropriate antidiuresis. N Engl J Med 2007, 356, 2064–2072.
  24. Renneboog B, Musch W, Vandemergel X, Manto M.U, Decaux G, Hon F: Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006, 119, 71.e1–71.e8.
  25. Kengne FG, Andres C, Sattar L, Melot C, Decaux G: Mild hyponatremia and risk of fracture in the ambulatory elderly. Q J Med 2008, 101, 583–588.
  26. Zilberberg MD, Exuzides A, Spalding J, Foreman A, Graves Jones A, Colby C et al.: Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin 2008, 24(6), 1601–1608.
  27. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA: Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 2008, 19, 764–770.
  28. Lee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by convertingenzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73(2), 257–267.
  29. Gill G, Huda B, Boyd A, Skagen K, Wilet D, Watson I: Characteristics and mortality of severe hyponatremia – a hospital-based study. Clin Endocrinol 2006, 65, 246–249.
  30. Waikar SS, Mount DB, Curhan GC: Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009, 122, 857–865.
  31. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE: Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010, 170(3), 294–302.
  32. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA et al.: Hyponatremia-induced osteoporosis. J Bone Miner Res 2009, 25(3), 554–563.
  33. Kinsella S, Moran S, Sullivan MO, Molloy MGM, Eustace JA: Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010, 5, 275–280.
  34. Decaux G: Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001, 110, 582–584.